Paclitaxel plus gemcitabine may be as active and well tolerated as paclitaxel plus carboplatin for advanced non-small-cell lung cancer

References 

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899–909
2. Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J. Clin. Oncol. 2002;20:23S–33S
3. Chen YM, Perng RP, Lee YC, et al.  Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann. Oncol. 2002;13:108–115
   • MEDLINE
   • CrossRef
4. Raftopoulos H, Gralla RJ, Bria E, Eid A. Assessing the role of chemotherapy in advanced non-small cell lung cancer (NSCLC): a comprehensive review of large, randomized trials 1991–2001. Proc. Am. Soc. Clin. Oncol. 2002;21:a1284
5. Georgoulias V, Papadakis E, Alexopoulos A, et al.  Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001;357:1478–1484
   • Abstract
   • Full Text
   • Full-Text PDF (98 KB)
   • CrossRef
6. Schiller JH, Harrington D, Belani CP, et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 2002;346:92–98
7. Giaccone G. Early results of a randomized phase III trial of platinum-containing doublets versus a non-platinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975. Semin. Oncol. 2002;29(Suppl 9):47–49
   • Abstract
   • Full Text
   • Full-Text PDF (79 KB)
   • CrossRef